BRCC3: A Potential Drug Target for Cancer (G79184)

Target Name: BRCC3

NCBI ID: G79184

BRCC3

BRCC3: A Potential Drug Target for Cancer

BRCC3, also known as BRCA3, is a protein that is expressed in various tissues of the body, including the brain, heart, and breast. It is a subunit of the BRCA1 and BRCA2 complex, which are tumor suppressor genes that have been implicated in the development of various diseases, including breast and ovarian cancer. The BRCC3 protein has been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis.

Diseases associated withBRCC3
Several studies have suggested that BRCC3 may be involved in the development and progression of various diseases, including breast and ovarian cancer. For example, it has been shown to be overexpressed in various breast and ovarian tumors, and may contribute to their aggressive behavior. Additionally, BrCC3 has been shown to be involved in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. This is important because the regulation of apoptosis is a key factor in the development and progression of cancer.

The BRCA1 and BRCA2 genes are known to be tumor suppressor genes that have been implicated in the development of breast and ovarian cancer. These genes have been shown to have a role in the regulation of cell growth, apoptosis, and angiogenesis. BRCC3, as a subunit of the BRCA1 and BRCA2 complex, may be involved in the regulation of these processes.

TargetingBRCC3
BRCC3 is a protein that can be targeted by various therapeutic approaches, including small molecules, antibodies, and gene therapy. Small molecules have been shown to be effective in inhibiting the activity of BRCC3, and antibodies have been shown to be effective in blocking the interaction of BRCC3 with other proteins. Additionally, gene therapy has been shown to be effective in treating various diseases, including breast and ovarian cancer, by introducing new genes that can replace or modify the BRCC3 gene.

Conclusion
BRCC3 is a protein that has been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis. It has also been implicated in the development and progression of various diseases, including breast and ovarian cancer. As such, it may be a potential drug target or biomarker for the treatment of these diseases. Further research is needed to fully understand the role of BRCC3 in the development and progression of cancer, as well as to develop effective therapies that target it.

Protein Name: BRCA1/BRCA2-containing Complex Subunit 3

Functions: Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs) (PubMed:14636569, PubMed:19202061, PubMed:16707425, PubMed:17525341, PubMed:19261748, PubMed:19261749, PubMed:19261746). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:20656690, PubMed:24075985, PubMed:26195665, PubMed:26344097). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985, PubMed:26344097). Acts as a regulator of the NLRP3 inflammasome by mediating deubiquitination of NLRP3, leading to NLRP3 inflammasome assembly (By similarity). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985). Deubiquitinates HDAC1 and PWWP2B leading to their stabilization (By similarity)

The "BRCC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRCC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets